CA Patent

CA3022535A1 — Semaglutide in cardiovascular conditions

Assigned to Novo Nordisk AS · Expires 2017-11-02 · 9y expired

What this patent protects

The present invention relates to the GLP-1 receptor agonist semaglutide for use in medicine.

USPTO Abstract

The present invention relates to the GLP-1 receptor agonist semaglutide for use in medicine.

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

Patent Metadata

Patent number: CA3022535A1
Jurisdiction: CA
Classification: —
Expires: 2017-11-02
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.